Higher doses tend to bring more noticeable side effects than starter doses
Pooled analysis reported no significant effect on ventricular fibrillation outcomes from treatment with GLP-1RA versus placebo [RR=1.00, 95% CI (0.50, 2.02), p =1.00]
Dihexa opens an original HGF/c-Met pathway, despite the rarity of independent replications
doi: 10.3389/fnins.2025.1587818 Received 06 March 2025 Accepted 09 May 2025 Published 04 June 2025 Volume 19 - 2025 Edited by Stefano Marini, Independent Researcher, Termoli, Italy Reviewed by Elizabeth Anne McCullagh, Oklahoma State University, United States Hanif Ullah, Sichuan University, China Updates Copyright 2025 Fang, Zhou, Chen, Wang, Liu and Jia
Nausea, constipation, bloating, reflux, and early satiety are some of the most common complaints, especially during dose escalation
For Pfizer, the Sciwind partnership is another solid step to advance Pfizers global strategy in the metabolic field and reflects our ambition to become a leader in the generation of chronic weight management therapies, Alexandre de Germay, the pharmas chief international commercial officer, said in a statement
